Aspen Epirubicin Injection
PDF Leaflet Revision Date: 12 June 2009
Clinical Summary
Quick overview from the medicine insert
Indication
Monotherapy for various neoplasms including breast and gastric carcinomas.
Dosage (summary)
60 to 90 mg/mu00b2 body surface area, repeated every 21 days; up to 135 mg/mu00b2 for advanced breast cancer.
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; avoid pregnancy and breastfeeding.
Key Drug Interactions
- Cimetidine increases epirubicin concentration
- Avoid mixing with heparin
- Cardio-active compounds may increase cardiotoxicity
Common side effects
- Leucopenia
- Nausea
- Vomiting
- Alopecia
- Cardiotoxicity
Counselling Points
- Monitor for signs of infection
- Avoid contact sports
- Report any bleeding or bruising
Serious warnings
- Cardiac monitoring required
- Risk of myelosuppression
- Avoid immunisations without approval
Important Disclaimer
The Aspen Epirubicin Injection professional information leaflet below is the property of Aspen Pharmacare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
